A new board aims to turn aging into a treatable target, using AI to move from reactive care to longer and healthier lives.
What if medicine stopped chasing disease and started chasing time? For most of modern healthcare, the script has been predictable: wait for something to go wrong, then treat it. A diagnosis appears, a drug follows. However, what if the real target isn’t the disease at all? What if it’s the slow, underlying process that makes those diseases more likely in the first place?
These are the questions Insilico Medicine is leaning into with the launch of what it calls the industry’s first Longevity Board, a group designed to guide how artificial intelligence can be used to develop drugs that don’t just treat illness, but intervene in aging itself [1]. Instead of fixing things once they break, try to slow down the biological wear and tear that leads to breakdown in the first place.
At the center of this move is Andrew Adams of Eli Lilly and Company, who will chair the board. Longevity science has, for years, lived in two separate worlds. On one side, researchers exploring the deep biology of aging – complex, promising, but often hard to translate into actual medicines. On the other, large pharmaceutical companies that know how to bring drugs to market, but haven’t always prioritized aging as a target.
Adams sits squarely in between. His appointment suggests that longevity is no longer content with being a research curiosity. It wants to become a product that is regulated, scalable and prescribed. That changes the stakes because once longevity enters the machinery of pharma, it’s no longer just about possibility.
The phrase “antiaging” has always carried a certain baggage – overpromising, underdelivering, often drifting into the territory of wishful thinking. What’s emerging now is more pragmatic. Instead of trying to “reverse aging,” companies like Insilico are focusing on conditions that sit right next to it: obesity, muscle loss, metabolic disorders, fibrosis and even chronic diseases.
Diseases are also expressions of how the body changes over time. Think of aging like a system slowly losing calibration. Different parts drift at different speeds, but they’re all connected.
Insilico’s strategy is to identify what it calls “dual-purpose targets,” biological pathways that influence both disease and aging. If you can adjust those pathways, you’re not just treating one condition; you’re potentially nudging the entire system back toward balance. It’s not a shortcut, but it’s a path that regulators, investors and clinicians can actually follow.
Aging is messy. It doesn’t happen in one place or for one reason. It’s a network problem – genes, proteins, cells and environments all interacting in ways that are hard to untangle. This is where AI becomes a necessity. Imagine trying to map a city by walking every street yourself. Now imagine having a satellite view that shows traffic patterns, bottlenecks and hidden connections all at once. That’s what AI is trying to bring to drug discovery.
By processing vast amounts of biological data, AI can spot patterns that would take humans years (if not decades) to uncover. It can suggest which targets are worth pursuing, which combinations might work, and which paths are likely dead ends.
For Insilico, the Longevity Board, which includes the company’s CEO and Co-CEO, is about making sure that this computational power is pointed in the right direction and grounded in real biology.
A decade of groundwork, now taking shape
For Michael Levitt, who joins the Board, this moment reflects how far the field has come and how much further it still has to go.
“Longevity science has matured enormously since Alex and I began working together over a decade ago. What excites me most about this Board is the combination of rigorous biological insight with the kind of large-scale computational power that can actually move the needle, ” he said.
Levitt expressed his perspective that aging should not be viewed as a single, isolated problem, but rather as a complex, deeply interconnected network of molecular and cellular processes. He emphasized that the only realistic opportunity to extend both human lifespan and healthspan lies in systematically addressing this complexity using AI tools capable of mapping such intricate systems.
Moreover, he also expressed pride in contributing to an initiative he characterized as scientifically grounded, serious and sufficiently ambitious to achieve meaningful results. His point lands clearly: aging isn’t one thing you can “solve.” It’s a system you have to understand well enough to influence, and that requires both patience and scale.
Where does this leave longevity now
The creation of a Longevity Board might seem like an internal move, but it reflects a broader shift happening across the industry. Longevity is becoming organized, structured and accountable.
Maybe that’s what the field has been missing all along. Extending life isn’t just about adding years; it’s about keeping people healthier for longer, delaying the onset of disease, compressing the period of decline. What Insilico is building is not a single breakthrough, but a framework, a way to turn longevity from an idea into a pipeline.
If it succeeds, the impact will be gradual, almost invisible – fewer chronic conditions, later in life; treatments that feel less like rescue and more like maintenance. In other words, a shift from reacting to aging… to managing it. That, more than anything, is what makes this moment feel new. We’re finally starting to treat it as something we can work on, systematically and at scale.
Photographs courtesy of Insilico Medicine
[1] https://insilico.com/news/vxuidy8ph1-insilico-medicine-announces-industrys-fi
